Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis D, Gastinne T, Ma S, Cohen JB, Patel K, Brown JR, Scarfò L, Munir T, Lech-Maranda E, Hoffmann MS, Ujjani CS, Fakhri B, Wang ML, Izutsu K, Nagai H, Tam CS, Rhodes JM, Vose J, McKinney M, Gerson JN, Barve MA, Kuss B, Koh Y, Barrett A, Treon SP, Castillo JJ, Seymour JF, Ruppert AS, McNeely SC, Walgren RA, Tsai DE, Bao K, Nair B, Woyach J, Cheah CY

Open source

DOI: 10.1016/s2352-3026(26)00037-2
Published: 2026 May
Container: The Lancet. Haematology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-26-00037-2,
  title = {Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.},
  author = {Palomba ML and Patel MR and Eyre TA and Jurczak W and Lewis D and Gastinne T and Ma S and Cohen JB and Patel K and Brown JR and Scarfò L and Munir T and Lech-Maranda E and Hoffmann MS and Ujjani CS and Fakhri B and Wang ML and Izutsu K and Nagai H and Tam CS and Rhodes JM and Vose J and McKinney M and Gerson JN and Barve MA and Kuss B and Koh Y and Barrett A and Treon SP and Castillo JJ and Seymour JF and Ruppert AS and McNeely SC and Walgren RA and Tsai DE and Bao K and Nair B and Woyach J and Cheah CY},
  year = {2026},
  journal = {The Lancet. Haematology},
  doi = {10.1016/s2352-3026(26)00037-2},
  url = {https://doi.org/10.1016/s2352-3026(26)00037-2}
}

RIS

TY  - JOUR
TI  - Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
AU  - Palomba ML
AU  - Patel MR
AU  - Eyre TA
AU  - Jurczak W
AU  - Lewis D
AU  - Gastinne T
AU  - Ma S
AU  - Cohen JB
AU  - Patel K
AU  - Brown JR
AU  - Scarfò L
AU  - Munir T
AU  - Lech-Maranda E
AU  - Hoffmann MS
AU  - Ujjani CS
AU  - Fakhri B
AU  - Wang ML
AU  - Izutsu K
AU  - Nagai H
AU  - Tam CS
AU  - Rhodes JM
AU  - Vose J
AU  - McKinney M
AU  - Gerson JN
AU  - Barve MA
AU  - Kuss B
AU  - Koh Y
AU  - Barrett A
AU  - Treon SP
AU  - Castillo JJ
AU  - Seymour JF
AU  - Ruppert AS
AU  - McNeely SC
AU  - Walgren RA
AU  - Tsai DE
AU  - Bao K
AU  - Nair B
AU  - Woyach J
AU  - Cheah CY
PY  - 2026
JO  - The Lancet. Haematology
DO  - 10.1016/s2352-3026(26)00037-2
UR  - https://doi.org/10.1016/s2352-3026(26)00037-2
ER  -

APA

ML, P., MR, P., TA, E., W, J., D, L., T, G., S, M., JB, C., K, P., JR, B., L, S., T, M., E, L., MS, H., CS, U., B, F., ML, W., K, I., H, N., CS, T., JM, R., J, V., M, M., JN, G., MA, B., B, K., Y, K., A, B., SP, T., JJ, C., JF, S., AS, R., SC, M., RA, W., DE, T., K, B., B, N., J, W., & CY, C. (2026). Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.. The Lancet. Haematology. https://doi.org/10.1016/s2352-3026(26)00037-2

Source records

pubmed · retrieved 2026-09-26T02:13:55.786Z